AR127050A1 - Compuestos espirocíclicos - Google Patents

Compuestos espirocíclicos

Info

Publication number
AR127050A1
AR127050A1 ARP220102479A ARP220102479A AR127050A1 AR 127050 A1 AR127050 A1 AR 127050A1 AR P220102479 A ARP220102479 A AR P220102479A AR P220102479 A ARP220102479 A AR P220102479A AR 127050 A1 AR127050 A1 AR 127050A1
Authority
AR
Argentina
Prior art keywords
spirocyclic compounds
compounds
refers
processes
formula
Prior art date
Application number
ARP220102479A
Other languages
English (en)
Inventor
James Michael Smith
Graeme Richard Robb
Piotr Antoni Raubo
Bernard Christophe Barlaam
Iain Alexander Cumming
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR127050A1 publication Critical patent/AR127050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La memoria descriptiva se refiere a compuestos de fórmula (1) y sales farmacéuticamente aceptables de estos. La memoria descriptiva también se refiere a procesos y productos intermedios usados para su preparación, a composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos proliferativos celulares.
ARP220102479A 2021-09-13 2022-09-13 Compuestos espirocíclicos AR127050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163243267P 2021-09-13 2021-09-13

Publications (1)

Publication Number Publication Date
AR127050A1 true AR127050A1 (es) 2023-12-13

Family

ID=83688613

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102479A AR127050A1 (es) 2021-09-13 2022-09-13 Compuestos espirocíclicos

Country Status (13)

Country Link
US (1) US11939344B2 (es)
JP (1) JP7406674B2 (es)
KR (1) KR102624567B1 (es)
CN (1) CN117916241A (es)
AR (1) AR127050A1 (es)
AU (1) AU2022343903A1 (es)
CA (1) CA3230648A1 (es)
CO (1) CO2024002844A2 (es)
DO (1) DOP2024000041A (es)
IL (1) IL311254A (es)
PE (1) PE20240886A1 (es)
TW (1) TW202330538A (es)
WO (1) WO2023036974A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024038004A1 (en) 2022-08-15 2024-02-22 Astrazeneca Ab Mta-cooperative prmt5 inhibitors for use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
WO2010017047A1 (en) * 2008-08-05 2010-02-11 Merck & Co., Inc. Therapeutic compounds
UA123786C2 (uk) 2016-04-06 2021-06-02 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка mdm2
JP2022504541A (ja) 2018-10-08 2022-01-13 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 低分子ｍｄｍ２タンパク質デグレーダー

Also Published As

Publication number Publication date
DOP2024000041A (es) 2024-04-15
CN117916241A (zh) 2024-04-19
KR20230091198A (ko) 2023-06-22
JP7406674B2 (ja) 2023-12-27
WO2023036974A1 (en) 2023-03-16
JP2023549418A (ja) 2023-11-24
US11939344B2 (en) 2024-03-26
US20230357279A1 (en) 2023-11-09
KR102624567B1 (ko) 2024-01-11
CO2024002844A2 (es) 2024-03-18
TW202330538A (zh) 2023-08-01
AU2022343903A1 (en) 2024-05-02
PE20240886A1 (es) 2024-04-24
IL311254A (en) 2024-05-01
CA3230648A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
UY38602A (es) Compuestos tricíclicos condensados
NI202000078A (es) Compuestos heteroaril tetracíclicos
CR20190204A (es) Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer
UY38001A (es) Compuestos que inhiben las proteínas ras mutantes g12c
ECSP21004787A (es) Inhibidores de inflamasoma nlrp3
ECSP20053845A (es) Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
CO6251367A2 (es) Derivados de 6-amino-5-aril piridina-2il-carboxamida
CR20190379A (es) Moduladores del receptor de estrógeno
DOP2010000387A (es) Compuestos pirazolicos 436
UY33491A (es) ?Derivados de sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina?.
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
CO2024002844A2 (es) Compuestos espirocíclicos
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
CO2022004723A2 (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
CO2022004698A2 (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
ECSP22049160A (es) Derivados de bencimidazol
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
UY39588A (es) Pirazolotiazol carboxamidas y usos de estas como inhibidores de pdgfr
EA202192366A1 (ru) Конденсированные трициклические соединения, применимые в качестве противораковых средств
AR111416A2 (es) Compuesto terapéutico para el dolor y síntesis del compuesto
CU20100250A7 (es) Compuestos pirazólicos 436